Synthesis of 14-Alkoxymorphinan Derivatives and Their Pharmacological Actions

被引:18
作者
Schmidhammer, Helmut [1 ,2 ]
Spetea, Mariana [1 ,2 ]
机构
[1] Univ Innsbruck, Dept Pharmaceut Chem, Inst Pharm, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, CMBI, A-6020 Innsbruck, Austria
来源
CHEMISTRY OF OPIOIDS | 2011年 / 299卷
基金
奥地利科学基金会;
关键词
14-Alkoxymorphinans; Opioid agonist; Opioid antagonist; Opioid receptors; Opioids; OPIOID RECEPTOR ANTAGONISTS; ACID-SUBSTITUTED DERIVATIVES; BIOLOGICAL EVALUATION; HIGHLY POTENT; MEDIATED ANTINOCICEPTION; OPIATE AGONISTS; BINDING-SITES; IN-VITRO; DELTA; MU;
D O I
10.1007/128_2010_77
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Among opioids, morphinans play an important role as therapeutically valuable drugs. They include pain relieving agents such as naturally occurring alkaloids (e. g. morphine, codeine), semisynthetic derivatives (e. g. oxycodone, oxymorphone, buprenorphine), and synthetic analogs (e. g. levorphanol). Currently used opioid analgesics also share a number of severe side effects, limiting their clinical usefulness. The antagonist morphinans, naloxone and naltrexone are used to treat opioid overdose, opioid dependence, and alcoholism. All these opioid drugs produce their biological actions through three receptor types, mu, delta, and kappa, belonging to the G-protein-coupled receptor family. Considerable effort has been put forward to understand the appropriate use of opioid analgesics, while medicinal chemistry and opioid pharmacology have been continuously engaged in the search for safer, more efficacious and nonaddicting opioid compounds, with the final goal to reduce complications and to improve patient compliance. Toward this goal, recent advances in chemistry, ligand-based structure activity relationships and pharmacology of 14-alkoxymorphinans are reviewed in this chapter. Current developments of different structural patterns of 14-alkoxymorphinans as research tools and their potential therapeutic opportunities are also summarized.
引用
收藏
页码:63 / 91
页数:29
相关论文
共 108 条
[1]   DAMGO and 6β-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens [J].
Al-Khrasani, Mahmoud ;
Spetea, Mariana ;
Friedmann, Tamas ;
Riba, Pal ;
Kiraly, Kornel ;
Schmidhammer, Helmut ;
Furst, Susanna .
BRAIN RESEARCH BULLETIN, 2007, 74 (05) :369-375
[2]  
ARAKAWA K, 1992, TRANSPLANT P, V24, P696
[3]  
ARAKAWA K, 1993, TRANSPLANT P, V25, P738
[4]   Peripherally mediated antinociception of the μ-opioid receptor agonist 2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl) amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation [J].
Bileviciute-Ljungar, I ;
Spetea, M ;
Guo, Y ;
Schütz, J ;
Windisch, P ;
Schmidhammer, H .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (01) :220-227
[5]  
Biyashev D, 2001, HELV CHIM ACTA, V84, P2015, DOI 10.1002/1522-2675(20010711)84:7<2015::AID-HLCA2015>3.0.CO
[6]  
2-1
[7]  
BLUMBERG H, 1966, P SOC EXP BIOL MED, V123, P755
[8]   Endogenous opiates and behavior: 2008 [J].
Bodnar, Richard J. .
PEPTIDES, 2009, 30 (12) :2432-2479
[9]   CHARACTERIZATION OF OPIOID RECEPTOR TYPES AND SUBTYPES WITH NEW LIGANDS [J].
BORSODI, A ;
TOTH, G .
DIVERSITY OF INTERACTING RECEPTORS, 1995, 757 :339-352
[10]   OPIOID AGONIST AND ANTAGONIST ACTIVITIES OF PERIPHERALLY SELECTIVE DERIVATIVES OF NALTREXAMINE AND OXYMORPHAMINE [J].
BOTROS, S ;
LIPKOWSKI, AW ;
LARSON, DL ;
STARK, PA ;
TAKEMORI, AE ;
PORTOGHESE, PS .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (09) :2068-2071